C. Diff. Spores And More

Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center. A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.” - Presented by: Dr. David Lyerly, Co-founder and Chief Science Officer of TECHLAB, Inc. Aerosol Transmission of Pathogens: The Problem and the Solutions. Presented by: Maureen Spencer, RN, M.ED., CIC

Inaugural Dale Gerding Lifetime Achievement Award - Presented by Sahil Khanna, MBBS MS, Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic to Dale Gerding, MD, FACP, FIDSA. Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues. - Presented by: Dr. Dale Gerding, MD, FACP, FIDSA, Retired Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. “Antimicrobial Stewardship and Its Impact On C difficile.” - Presented by: Glenn Tillotson, PHD, FIDSA, FRSM,, FCCP, FISC, Senior Consultant, Global ID, Anti-Infective Drug Development, GST Micro LLC. Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center

“Introducing a New Disinfection Technology Against C. diff.” Jordan Bastian (Speaker) Infection Preventionist, CloroxPro Clinical and Scientific Affairs, Clorox Company Ibezapolstat Update: Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect? Kevin Garey (Speaker) Chair of the Department of Pharmacy Practice and Translational Research and Professor of Pharmacy Practice, University of Houston College of Pharmacy More Than a CDI: The Revolving Door and a Ray Of Hope. Kathy Bischoff (Speaker) Coordinator, VHA Program, C Diff Foundation Sponsored by ACURX Pharmaceuticals Clorox Healthcare

We welcome our guest, Madeline King, PharmD, BCIDP Assistant Professor of Clinical Pharmacy, Infectious Diseases, Department of Pharmacy Practice & Pharmacy Administration. Dr. King joins us to discuss the updated Clostridioides difficile (C. difficile) Guidelines, along with topic of Antibiotics. Dr. King has a passion in infectious disease, public health, and truly enjoys teaching.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 6 Group Discussion I ‘Recent Developments in Diagnosis, Treatment, and Prevention of C. difficile infections In Children.’ GROUP DISCUSSION I Thursday Afternoon Speakers Thomas J. Sandora, MD MPH (Speaker) Associate Professor of Pediatrics : PANELIST, Harvard Medical School : Panel Discussion I Larry Kociolek, MD (Speaker) Attending Physician, Ann & Robert H. Lurie Children’s Hospital Maribeth Nicholson, MD, MPH (Speaker) Assistant Professor of Pediatrics, Vanderbilt University Medical Center. --- 'Introduction to Microbiota and Microbiota Restoration for Recurrent C diff infections' Ken Blount, Ph.D. (Speaker) Chief Scientific Officer, Rebiotix, Inc a Ferring Company ---- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 5 A Caregiver's Journey David Bischoff (Speaker) Co-Coordinator VHA Program, C Diff Foundation A Caregiver's Perspective ~ Caring For a Loved One Diagnosed With a CDI --- “Is this C.diff.? How IBS and IBD Complicate the Diagnosis and Management of Patients With a CDI” Caterina Oneto, MD (Speaker) Clinical Instructor, Division of Gastroenterology, NYU --- “The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 4 --- 'Using a Gut Model to Predict Which Antibiotics Are Associated with CDI and Which Ones Best Treat CDI' Mark Wilcox, MD, FRCPath (Speaker) Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology, Leeds Teaching Hospitals --- Microbiome Therapeutics in 2021: Almost there for C difficile! Sahil Khanna, MBBS MS (Speaker) Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 3 Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis. Florence Sejourne (Speaker) CEO, DA VOLTERRA --- “Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies” Beth Guthmueller (Speaker) Rebiotix, a Ferring Company --- ‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’ Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 2 “The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy ** Results from ECOSPOR III, a Phase 3 Placebo-Controlled Trial of SER-109, an Investigational Microbiome Therapeutic to Reduce Recurrence of Clostridioides difficile Infection Barbara McGovern, MD (Speaker) VP, Medical Affairs, Seres Therapeutics ** Evidence-Based Hand Hygiene In the Post-COVID World.” Tamas Haidegger (Speaker) Associate Professor, Óbuda University ** We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 1 Paul Feuerstadt, MD, FACG, AGAF introduce the C Diff Foundation and provide an overview of a C. difficile infection. Simon M. Cutting, Ph.D. will present: What Makes Us Susceptible to a C. difficile Infection? We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

Join us with our guests from GoodNature, a Seres Therapeutics program; April Garcia, Site Manager of GoodNature Irvine California, and two GoodNature donors who will share their experiences. They will discuss the who, what, and how in donating poop to potentially support C. diff patients. With microbiome therapeutics on the forefront, it will be an educational discussion.

Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times of Microbiome Restoration For C. difficile infections and how we are almost there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.

Join us with our guest; Ken Blount PhD, CSO Rebiotix Inc, a Ferring Company and VP Microbiome Research Ferring - as Dr. Blount introduces the gut microbiome. There is so much to learn about this cutting edge science, along with a discussion about the recurrence of a C. difficile infection , and how clinical trials work.. The gut microbiome has a direct connection to our health and Dr. Blount will be shining some light on this educational topic Have your mobile devices or a pen and notebook ready as we learn more about the gut microbiome, C. difficile infections, clinical trials, and much more!

Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA). Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy w

Join Nancy C. Caralla and Kevin Hersh as we discuss the chapters and passion behind the newly published book, Managing a C. difficile Infection: For Patients, Families, and Caregivers.

Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis. The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most. sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly. September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day. For more information please visit: https://www.global-sepsis-

Wendy Benson is partner and COO at 2x2 Health: Private Health Concierge, culminating from her extensive experience as a leading healthcare executive and occupational therapist. She is also co-author of the international best-selling book, The Confident Patient. Wendy joins us to discuss the necessity of becoming a strong health advocate and ways to manage care through unprecedented times.

Join Doctors Caterina Oneto, and Paul Feuerstadt, as they discuss the Management of C. difficile Infections. The new guidelines released by IDSA and SHEA this June along with the new treatments on the horizon will also be a topic of conversation.